Le Lézard
Classified in: Health, Science and technology
Subject: Funding

Schrödinger Announces Close of Latest Financing, Raising Total of $110 Million


Schrödinger today announced that several new investors have joined its latest funding round, which was completed with a total raise of $110 million to support continued advancement of the company's industry-leading computational platform and expansion of its therapeutic pipeline.

New investors include Invus, Pavilion Capital, Oculus co-founder Michael Antonov through his investment fund, Tubus Management, Laurion Capital Management, and others. Previous investors in the round included the Bill and Melinda Gates Foundation Trust, WuXi AppTec's Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).

"Our platform has been validated again and again across hundreds of targets in real-world drug discovery projects," said Schrödinger CEO Ramy Farid, Ph.D. "We are committed to leveraging the platform to speed the discovery of new medicines, and we're delighted to receive such broad support from investors to further our mission."

The funding will support the advancement of Schrödinger's wholly-owned drug discovery pipeline and enable continued expansion of the company's collaborations with biopharma companies worldwide. These partnerships have already led to two FDA-approved oncology drugs, several clinical-stage assets, and more than two dozen additional programs moving through discovery and development.

The investment will also support Schrödinger's ongoing research and development efforts to extend the reach of its proprietary technology platform, which integrates novel physics-based molecular simulations and machine learning to enable exploration of vastly more chemical space than is possible through traditional drug discovery methods. This expanded and accelerated exploration opens new frontiers for discovery of novel compounds for both therapeutic indications and materials design.

About Schrödinger

Schrödinger has a substantial and growing global business, licensing its industry-leading computational platform to pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R&D in both drug discovery and materials design. Schrödinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. Schrödinger's significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world. Visit schrodinger.com for more information.


These press releases may also interest you

at 15:00
Keene Family of Companies announces an addition to its portfolio. Barrett Company has been acquired and will join Keene Family of Companies: Keene Building Products, Dependable, LLC, Continental Products, Ltd and Keene Village Plastics. Barrett was...

at 14:53
Enables powerful NVIDIA T4 GPU accelerators in Dell EMC PowerEdge MX  News Highlights: The innovative solution combines up to 16 NVIDIA T4 Tesla GPUs within the Dell EMC PowerEdge MX7000 modular chassis to handle today's graphically demanding...

at 14:00
While most reverse mortgage lenders have felt the squeeze since changes to regulations were implemented almost two years ago, the commitment by VIP Mortgage to offer retirement strategies for the baby boomer population has helped its Reverse Mortgage...

at 13:00
The member companies of the Utica National Insurance Group will now offer cognitive baseline and post-injury concussion testing to its public and private school policyholders through the world's leading concussion management software company, ImPACT...

at 11:00
Ricky Nguyen is a lifelong entrepreneur and the host of the lifestyle and business podcast Millennial Movement. He's gone from selling lemonade and sneakers to hosting one of the top 150 podcasts and tells us where he's going in the future. Ricky...

at 07:00
Authors Gopal Nayak and Mahendra Kumar Trivedi were recognized with International No. 1 best-selling author status for the scientific research book "Impact of Biofield Treatment on Growth and Anatomical Characteristics of Pogostemon cablin (Benth.)...



News published on 19 may 2019 at 07:05 and distributed by: